Table 2 Risk factors control and medications in T2DM and CKD group and T2DM only group of Beijing and Taiyuan
Parameters | Beijing | Taiyuan | ||||||
|---|---|---|---|---|---|---|---|---|
overall (n = 858) | Group 1 (n = 336) | Group 2 (n = 522) | P | overall (n = 1085) | Group 1 (n = 243) | Group 2 (n = 842) | P | |
HbA1c (%) | 8.4 (7.1, 9.9) | 8.7 (7.5, 10.1) | 8.1 (7.0, 9.7) | < 0.001 | 8.5 (7.2, 10.1) | 9.2 (7.9, 10.8) # | 8.2 (7.1, 10.0) | < 0.001 |
< 7.0 | 183 (21.3) | 57 (17.0) | 126 (24.1) | 0.002 | 214 (19.7) | 23 (9.5) * | 191 (22.7) | < 0.001 |
7.0–8.9 | 342 (39.9) | 125 (37.2) | 217 (41.6) | 424 (39.1) | 86 (35.4) | 338 (40.1) | ||
≥ 9.0 | 333 (38.8) | 154 (45.8) | 179 (34.3) | 447 (41.2) | 134 (55.1) | 313 (37.2) | ||
SBP (mmHg) | 131 (120, 147) | 136 (125, 150) | 130 (120, 142) | < 0.001 | 130 (120, 140) # | 138 (125, 150) | 130 (120, 140) | < 0.001 |
DBP (mmHg) | 80 (72, 87) | 80 (71, 90) | 80 (72, 86) | 0.252 | 80 (70, 86) # | 80 (71, 88) | 79 (70, 85) | 0.007 |
BP ≥ 130/80 mmHg | 616 (71.8) | 260 (77.4) | 356 (68.2) | 0.004 | 739 (68.1) | 188 (77.4) | 551 (65.4) | < 0.001 |
LDL-C (mmol/L) | 2.93 (2.32, 3.55) | 2.92 (2.39, 3.56) | 2.94 (2.26, 3.54) | 0.549 | 2.83 (2.24, 3.46) # | 2.96 (2.32, 3.57) | 2.80 (2.23, 3.39) | 0.045 |
LDL-C ≥ 2.6 mmol/L | 551 (64.2) | 214 (63.7) | 337 (64.6) | 0.796 | 661 (60.9) | 157 (64.6) | 504 (59.9) | 0.181 |
TG (mmol/L) | 1.63 (1.13, 2.43) | 1.79 (1.19, 2.74) | 1.54 (1.11, 2.23) | 0.001 | 1.73 (1.24, 2.50) * | 1.87 (1.30, 2.92) | 1.69 (1.21, 2.38) | 0.003 |
TG ≥ 1.7 mmol/L | 410 (47.8) | 183 (54.5) | 227 (43.5) | 0.002 | 556 (51.2) | 136 (56.0) | 420 (49.9) | 0.095 |
Hyperuricemia | 250 (29.2) | 124 (36.9) | 126 (24.3) | < 0.001 | 203 (18.8) # | 70 (28.8) * | 133 (15.9) | < 0.001 |
BMI (kg/m2) | 26.1 (23.9, 28.4) | 26.6 (24.2, 28.9) | 25.8 (23.7, 28.0) | 0.001 | 25.1 (23.1, 27.3) | 25.4 (23.5, 27.7) # | 25.1 (23.1, 27.1) | 0.158 |
Normal | 219 (25.5) | 75 (22.3) | 144 (27.6) | 0.003 | 364 (33.5) # | 71 (29.2) # | 293 (34.8) | 0.253 |
Overweight | 381 (44.4) | 138 (41.1) | 243 (46.6) | 502 (46.3) | 118 (48.6) | 384 (45.6) | ||
Obesity | 258 (30.1) | 123 (36.6) | 135 (25.9) | 219 (20.2) | 54 (22.2) | 165 (19.6) | ||
Current smoker | 247 (28.8) | 106 (31.5) | 141 (27.0) | 0.152 | 192 (17.7) # | 49 (20.2) # | 143 (17.0) | 0.252 |
Current drinker | 179 (20.9) | 78 (23.2) | 101 (19.3) | 0.174 | 145 (13.4) # | 33 (13.6) # | 112 (13.3) | 0.910 |
No regular exercise | 798 (94.5) | 321 (96.4) | 477 (93.3) | 0.056 | 495 (45.7) # | 127 (52.5) # | 368 (43.8) | 0.017 |
Current medication | ||||||||
Insulin usage | 314 (36.6) | 147 (43.8) | 167 (32.0) | < 0.001 | 504 (46.5) # | 155 (63.8) # | 349 (41.4) | < 0.001 |
SGLT-2i usage | 29 (3.4) | 10 (3.0) | 19 (3.6) | 0.600 | 142 (13.1) # | 41 (16.9) # | 101 (12.0) | 0.047 |
ACEI/ARB usage | 194 (22.6) | 84 (25.0) | 110 (21.1) | 0.180 | 405 (37.3) # | 147 (60.5) # | 258 (30.6) | < 0.001 |
Statins usage | 230 (26.8) | 94 (28.0) | 136 (26.1) | 0.535 | 697 (64.2) # | 170 (70.0) # | 527 (62.6) | 0.035 |
Dyslipidemia therapy | 232 (27.0) | 96 (28.6) | 136 (26.1) | 0.418 | 743 (68.5) # | 186 (76.5) # | 557 (66.2) | 0.002 |
Follow up medication | ||||||||
Insulin usage | 511 (59.6) | 233 (69.3) | 278 (53.3) | < 0.001 | 528 (48.7) # | 164 (67.5) | 364 (43.2) | < 0.001 |
SGLT-2i usage | 430 (50.1) | 186 (55.4) | 244 (46.7) | 0.014 | 200 (18.4) # | 56 (23.0) | 144 (17.1) | 0.035 |
ACEI/ARB usage | 393 (45.8) | 181 (53.9) | 212 (40.6) | < 0.001 | 437 (40.3) * | 157 (64.6) | 280 (33.3) | < 0.001 |
Statins usage | 625 (72.8) | 258 (76.8) | 367 (70.3) | 0.037 | 719 (66.3) # | 178 (73.3) | 541 (64.3) | 0.009 |
Dyslipidemia therapy | 639 (74.5) | 264 (78.6) | 375 (71.8) | 0.027 | 764 (70.4) * | 191 (78.6) | 573 (68.1) | 0.002 |